Identification of side effects of COVID-19 drug candidates on embryogenesis using an integrated zebrafish screening platform.

ABSTRACT: Drug repurposing is an important strategy in COVID-19 treatment, but many clinically approved compounds have not been extensively studied in the context of embryogenesis, thus limiting their administration during pregnancy. Here we used the zebrafish embryo model organism to test the effects of 162 marketed drugs on cardiovascular development. Among the compounds used in the clinic for COVD-19 treatment, we found that Remdesivir led to reduced body size and heart functionality at clinically relevant doses. Ritonavir and Baricitinib showed reduced heart functionality and Molnupiravir and Baricitinib showed effects on embryo activity. Sabizabulin was highly toxic at concentrations only 5 times higher than C_max and led to a mean mortality of 20% at C_max. Furthermore, we

SUBMITTER: Ernst A 

PROVIDER: S-EPMC10562458 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature